301 related articles for article (PubMed ID: 35928724)
1. Establishment and evaluation of retroperitoneal liposarcoma patient-derived xenograft models: an ideal model for preclinical study.
Xu C; Yan L; An Q; Zhang S; Guan X; Wang Z; Lv A; Liu D; Liu F; Dong B; Zhao M; Tian X; Hao C
Int J Med Sci; 2022; 19(8):1241-1253. PubMed ID: 35928724
[TBL] [Abstract][Full Text] [Related]
2. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.
Zuco V; Pasquali S; Tortoreto M; Brich S; Percio S; Dagrada GP; Colombo C; Sanfilippo R; Lauricella C; Gounder M; El Bezawy R; Barisella M; Dei Tos AP; Casali PG; Gronchi A; Stacchiotti S; Zaffaroni N
J Exp Clin Cancer Res; 2021 Mar; 40(1):83. PubMed ID: 33648535
[TBL] [Abstract][Full Text] [Related]
3. Establishment and genetically characterization of patient-derived xenograft models of cervical cancer.
Zou S; Ye M; Zhang JA; Ji H; Chen Y; Zhu X
BMC Med Genomics; 2022 Sep; 15(1):191. PubMed ID: 36076209
[TBL] [Abstract][Full Text] [Related]
4. Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing.
Cornillie J; Wozniak A; Li H; Wang Y; Boeckx B; Gebreyohannes YK; Wellens J; Vanleeuw U; Hompes D; Stas M; Sinnaeve F; Wafa H; Lambrechts D; Debiec-Rychter M; Sciot R; Schöffski P
Mol Cancer Ther; 2019 Jun; 18(6):1168-1178. PubMed ID: 30962320
[TBL] [Abstract][Full Text] [Related]
5. Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models.
Okada S; Vaeteewoottacharn K; Kariya R
Cells; 2019 Aug; 8(8):. PubMed ID: 31412684
[TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of a non-gestational choriocarcinoma patient-derived xenograft model.
Oda Y; Niimi K; Yoshida K; Tamauchi S; Yokoi A; Yasui Y; Nishiko Y; Shibata M; Shimizu Y; Yoshihara M; Ikeda Y; Yoshikawa N; Nishino K; Yamamoto E; Kajiyama H
BMC Cancer; 2023 Nov; 23(1):1103. PubMed ID: 37957624
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of RRM2 Attenuates Retroperitoneal Liposarcoma Progression via the Akt/mTOR/4EBP1 Pathway: Clinical, Biological, and Therapeutic Significance.
Zhang S; Yan L; Cui C; Wang Z; Wu J; Lv A; Zhao M; Dong B; Zhang W; Guan X; Tian X; Hao C
Onco Targets Ther; 2020; 13():6523-6537. PubMed ID: 32753891
[TBL] [Abstract][Full Text] [Related]
8. Tsp2 Facilitates Tumor-associated Fibroblasts Formation and Promotes Tumor Progression in Retroperitoneal Liposarcoma.
Xu C; Yan L; Guan X; Wang Z; Wu J; Lv A; Liu D; Liu F; Dong B; Zhao M; Jia L; Tian X; Hao C
Int J Biol Sci; 2022; 18(13):5038-5055. PubMed ID: 35982904
[TBL] [Abstract][Full Text] [Related]
9. [Establishment of A Patient-derived Xenotransplantation Animal Model for Small Cell Lung Cancer and Drug Resistance Model].
Zhu Y; Huang W; Wu Y; Jia L; Li Y; Chen R; Guo L; Chen Q
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):6-14. PubMed ID: 30674387
[TBL] [Abstract][Full Text] [Related]
10. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice.
Chen Y; Zhang R; Wang L; Correa AM; Pataer A; Xu Y; Zhang X; Ren C; Wu S; Meng QH; Fujimoto J; Jensen VB; Antonoff MB; Hofstetter WL; Mehran RJ; Pisimisis G; Rice DC; Sepesi B; Vaporciyan AA; Walsh GL; Swisher SG; Roth JA; Heymach JV; Fang B
Cancer; 2019 Nov; 125(21):3738-3748. PubMed ID: 31287557
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.
Cornillie J; Wozniak A; Li H; Gebreyohannes YK; Wellens J; Hompes D; Debiec-Rychter M; Sciot R; Schöffski P
Clin Transl Oncol; 2020 Apr; 22(4):546-554. PubMed ID: 31201607
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma.
Choi B; Lee JS; Kim SJ; Hong D; Park JB; Lee KY
Cancer Lett; 2020 May; 478():56-69. PubMed ID: 32145342
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive immune characterization and T-cell receptor repertoire heterogeneity of retroperitoneal liposarcoma.
Yan L; Wang Z; Cui C; Guan X; Dong B; Zhao M; Wu J; Tian X; Hao C
Cancer Sci; 2019 Oct; 110(10):3038-3048. PubMed ID: 31385405
[TBL] [Abstract][Full Text] [Related]
14. Degree of
Bill KLJ; Seligson ND; Hays JL; Awasthi A; Demoret B; Stets CW; Duggan MC; Bupathi M; Brock GN; Millis SZ; Shakya R; Timmers CD; Wakely PE; Pollock RE; Chen JL
Oncologist; 2019 Jul; 24(7):989-996. PubMed ID: 31019022
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity.
Chen X; Shen C; Wei Z; Zhang R; Wang Y; Jiang L; Chen K; Qiu S; Zhang Y; Zhang T; Chen B; Xu Y; Feng Q; Huang J; Zhong Z; Li H; Che G; Xiao K
Cancer Biol Med; 2021 Feb; 18(1):184-198. PubMed ID: 33628593
[TBL] [Abstract][Full Text] [Related]
16. Identification of TYMS as a promoting factor of retroperitoneal liposarcoma progression: Bioinformatics analysis and biological evidence.
Zhang S; Yan L; Cui C; Wang Z; Wu J; Zhao M; Dong B; Guan X; Tian X; Hao C
Oncol Rep; 2020 Aug; 44(2):565-576. PubMed ID: 32627015
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies.
Liu L; Wu M; Huang A; Gao C; Yang Y; Liu H; Jiang H; Yu L; Huang Y; Wang H
J Transl Med; 2023 Sep; 21(1):611. PubMed ID: 37689699
[TBL] [Abstract][Full Text] [Related]
18. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
[TBL] [Abstract][Full Text] [Related]
19. Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts.
Kuwata T; Yanagihara K; Iino Y; Komatsu T; Ochiai A; Sekine S; Taniguchi H; Katai H; Kinoshita T; Ohtsu A
Cells; 2019 Jun; 8(6):. PubMed ID: 31207870
[TBL] [Abstract][Full Text] [Related]
20. Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers.
Kanaya N; Somlo G; Wu J; Frankel P; Kai M; Liu X; Wu SV; Nguyen D; Chan N; Hsieh MY; Kirschenbaum M; Kruper L; Vito C; Badie B; Yim JH; Yuan Y; Hurria A; Peiguo C; Mortimer J; Chen S
J Steroid Biochem Mol Biol; 2017 Jun; 170():65-74. PubMed ID: 27154416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
